Onasemnogene abeparvovec (Zolgensma) is the first gene therapy used to treat spinal muscular atrophy — a rare progressive and life-threatening condition that often begins in childhood and is caused by a genetic mutation.
Conditions for reimbursement include a price reduction and clinical criteria…
March 26, 2021
More than 35 evidence reviews are mapped to the prevention, identification, treatment, and management of tuberculosis, and accessible on a digital platform
With the publication of its first condition-level review, CADTH is giving Canadian policy-makers, clinicians, and patients quick access to…
March 24, 2021
CADTH is seeking nominations for its Board of Directors and expert committees. We are currently accepting applications from individuals with significant expertise in the Canadian health care system who are interested in helping support health care decision-makers in making informed choices about…
March 15, 2021
CADTH is partnering with Choosing Wisely Canada to identify actions that could lead to better post-pandemic care for Canadians. The organizations are developing recommendations for reducing low-value care that, if implemented, could make more resources available to deliver the priority services…
March 12, 2021
On February 25, CADTH issued our first provisional funding algorithm — a form of expert advice that supports provincial and territorial drug programs and cancer agencies in implementing our cancer drug reimbursement recommendations.
CADTH can issue a provisional funding algorithm when a new…
February 26, 2021
Suzanne McGurn, President and CEO of CADTH, is the featured guest on a new episode of The NPC Podcast (S03, E03). She talks with host Peter Brenders — CEO of the New Brunswick Health Research Foundation — about taking the reins at CADTH, how the pandemic has affected CADTH’s work, and the evolving…
February 19, 2021
New horizon scan report offers patients, providers, and decision-makers insight on key health technologies that could transform the delivery of care
OTTAWA, ON, February 17, 2021 — A new Watch List from CADTH identifies 10 emerging health technology trends that are poised to have a significant…
February 18, 2021
Feedback from more than 35 patient groups has helped CADTH update its Guidance for Providing Patient Input — a key resource for patient groups, patients, and caregivers who contribute to our reimbursement review process.
The guide now addresses some of the key improvements suggested by patient…
December 3, 2020
Voretigene neparvovec (Luxturna) is the first gene therapy evaluated through the CADTH reimbursement review process
CADTH recommends reimbursement with conditions, including a price reduction, and offers advice on implementing the recommendation
On November 16, CADTH recommended that Canada’s…
November 26, 2020
Did you miss some of the great live sessions during the 2020 Virtual CADTH Symposium?
Great news — our plenary and concurrent sessions are now available for on-demand viewing on the Symposium website.
In more great news, we’ve added 30 new pre-recorded sessions that will bring you fresh insights on…
November 25, 2020
After a Breakout Year for Digital Health, What’s Next?
This week, I’m proud to join Canadian health system leaders in celebrating Digital Health Week — a time to recognize how digital health is transforming the delivery of care.
When I think of the changes brought about by this pandemic, the “…
November 16, 2020
Today CADTH presented Recognition Awards to two scientists to honour their exceptional contributions to the field of health technology assessment (HTA) — one as a pioneer who has pushed the boundaries of economic evaluation in child health and the other as a rising star who is advancing the use of…
November 9, 2020